Foresight News 消息，据 Sonnet BioTherapeutics Holdings, Inc.（NASDAQ: SONN）发布的新闻稿，Sonnet 宣布其股东在特别会议上批准了与 Hyperliquid Strategies Inc（HSI）和 Rorschach I LLC 拟议的业务合并等事项。最终投票结果将以 Form 8-K 表格提交给美国证券交易委员会（SEC）。Sonnet 是一家专注于肿瘤学的生物技术公司，拥有专有的生物制剂创新平台 FHAB（Fully Human Albumin Binding）。该技术利用人血清白蛋白（HSA）将药物运输至靶组织，旨在提高免疫调节生物制剂的安全性和有效性。 [查看更多]
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.